NCT05468931 Prostate Stimulation for Sexual Dysfunction
| NCT ID | NCT05468931 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Sexual Dysfunction |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-04-18 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2024-04-18 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to use a device to stimulate the prostate with a goal of helping improve symptoms in men with sexual dysfunction.
Eligibility Criteria
Inclusion Criteria: * Males \>18 years of age suffering from sexual dysfunction Exclusion Criteria: * Individuals who have had a prostatectomy - removal of prostate * Inability to operate the device for any reason * Females * Males \<18 years of age
Contact & Investigator
Michael Eisenberg, M.D.
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT05468931 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Sexual Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05468931 currently recruiting?
Yes, NCT05468931 is actively recruiting participants. Contact the research team at sbasran@stanford.edu for enrollment information.
Where is the NCT05468931 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT05468931 clinical trial?
NCT05468931 is sponsored by Stanford University. The principal investigator is Michael Eisenberg, M.D. at Stanford University. The trial plans to enroll 15 participants.